Effect of immunosuppressive therapy in inflammatory
cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy
Immunosuppressive Trial

J 2022

Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial

POLOCZKOVÁ, Hana, Jan KREJČÍ, Petr HUDE, Eva OZÁBALOVÁ, Július GODAVA et. al.

Basic information

Original name

Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial

Authors

POLOCZKOVÁ, Hana (203 Czech Republic, belonging to the institution), Jan KREJČÍ (203 Czech Republic, guarantor, belonging to the institution), Petr HUDE (203 Czech Republic, belonging to the institution), Eva OZÁBALOVÁ (203 Czech Republic, belonging to the institution), Július GODAVA (703 Slovakia, belonging to the institution), Tomáš HONEK (203 Czech Republic, belonging to the institution), Víta ŽAMPACHOVÁ (203 Czech Republic, belonging to the institution), Iva SVOBODOVÁ (203 Czech Republic, belonging to the institution), Tomáš FREIBERGER (203 Czech Republic, belonging to the institution) and Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution)

Edition

Bratislava Medical Journal - Bratislavské lekárske listy, BRATISLAVA, Univerzita Komenského, 2022, 0006-9248

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.500

RIV identification code

RIV/00216224:14110/22:00128010

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.4149/BLL_2022_006

UT WoS

000748938700006

Keywords in English

myocarditis; inflammatory cardiomyopathy; endomyocardial biopsy; immunosuppressive therapy

Abstract

V originále

INTRODUCTION: The indications for specific treatment in the cases of inflammatory cardiomyopathy are based on limited data from several small clinical trials. AIM: A comparison of the effect of two dose regimens of combined immunosuppressive therapy by adding them to conventional heart failure therapy and comparing them with conventional heart failure therapy alone in patients with inflammatory cardiomyopathy. METHODS AND STUDY POPULATION: We enrolled 20 patients; mean age 46.10 +/- 7.33 years, duration of symptoms <6 months, LVEF <= 40 %, NYHA class II-IV, with biopsy-proven myocarditis. Patients were randomly separated into groups treated with immunosuppressive therapy in addition to conventional heart failure therapy or to a group treated with conventional heart failure therapy alone. Clinical and echocardiographic parameters were evaluated. RESULTS: The baseline values of LVEF in the group of immunosuppressive therapy (LVEF 22.3 +/- 4.7 %) were similar to those in the group treated with conventional heart failure therapy (LVEF 21.7 +/- 4.7 %; p=0.757). After twelve months there was no statistically significant difference in LVEF between the two studied groups (LVEF 33.7 +/- 9.5 % for the immunosuppressive therapy group and 41.3 +/- 13.0 % for the conventional therapy group; p=0.175). CONCLUSION: In our study population, we proved no positive effect of combined immunosuppressive therapy on the left ventricular function over 12 months. The main limitation of the study is the small number of enrolled patients.

Links

MUNI/A/1685/2020, interní kód MU

Name: Nové trendy v diagnostice a terapii kardiomyopatií

Investor: Masaryk University

Citovat

POLOCZKOVÁ, Hana, Jan KREJČÍ, Petr HUDE, Eva OZÁBALOVÁ, Július GODAVA, Tomáš HONEK, Víta ŽAMPACHOVÁ, Iva SVOBODOVÁ, Tomáš FREIBERGER and Lenka ŠPINAROVÁ. Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial. Bratislava Medical Journal - Bratislavské lekárske listy. BRATISLAVA: Univerzita Komenského, 2022, vol. 123, No 1, p. 37-43. ISSN 0006-9248. Available from: https://dx.doi.org/10.4149/BLL_2022_006.

@article{2247018,
   author = {Poloczková, Hana and Krejčí, Jan and Hude, Petr and Ozábalová, Eva and Godava, Július and Honek, Tomáš and Žampachová, Víta and Svobodová, Iva and Freiberger, Tomáš and Špinarová, Lenka},
   article_location = {BRATISLAVA},
   article_number = {1},
   doi = {http://dx.doi.org/10.4149/BLL_2022_006},
   keywords = {myocarditis; inflammatory cardiomyopathy; endomyocardial biopsy; immunosuppressive therapy},
   language = {eng},
   issn = {0006-9248},
   journal = {Bratislava Medical Journal - Bratislavské lekárske listy},
   title = {Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial},
   url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7503&category_id=179&option=com_virtuemart&vmcchk=1&Itemid=1},
   volume = {123},
   year = {2022}
}

TY  - JOUR
ID  - 2247018
AU  - Poloczková, Hana - Krejčí, Jan - Hude, Petr - Ozábalová, Eva - Godava, Július - Honek, Tomáš - Žampachová, Víta - Svobodová, Iva - Freiberger, Tomáš - Špinarová, Lenka
PY  - 2022
TI  - Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial
JF  - Bratislava Medical Journal - Bratislavské lekárske listy
VL  - 123
IS  - 1
SP  - 37-43
EP  - 37-43
PB  - Univerzita Komenského
SN  - 00069248
KW  - myocarditis
KW  - inflammatory cardiomyopathy
KW  - endomyocardial biopsy
KW  - immunosuppressive therapy
UR  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7503&category_id=179&option=com_virtuemart&vmcchk=1&Itemid=1
N2  - INTRODUCTION: The indications for specific treatment in the cases of inflammatory cardiomyopathy are based on limited data from several small clinical trials. AIM: A comparison of the effect of two dose regimens of combined immunosuppressive therapy by adding them to conventional heart failure therapy and comparing them with conventional heart failure therapy alone in patients with inflammatory cardiomyopathy. METHODS AND STUDY POPULATION: We enrolled 20 patients; mean age 46.10 +/- 7.33 years, duration of symptoms <6 months, LVEF <= 40 %, NYHA class II-IV, with biopsy-proven myocarditis. Patients were randomly separated into groups treated with immunosuppressive therapy in addition to conventional heart failure therapy or to a group treated with conventional heart failure therapy alone. Clinical and echocardiographic parameters were evaluated. RESULTS: The baseline values of LVEF in the group of immunosuppressive therapy (LVEF 22.3 +/- 4.7 %) were similar to those in the group treated with conventional heart failure therapy (LVEF 21.7 +/- 4.7 %; p=0.757). After twelve months there was no statistically significant difference in LVEF between the two studied groups (LVEF 33.7 +/- 9.5 % for the immunosuppressive therapy group and 41.3 +/- 13.0 % for the conventional therapy group; p=0.175). CONCLUSION: In our study population, we proved no positive effect of combined immunosuppressive therapy on the left ventricular function over 12 months. The main limitation of the study is the small number of enrolled patients.
ER  -

POLOCZKOVÁ, Hana, Jan KREJČÍ, Petr HUDE, Eva OZÁBALOVÁ, Július GODAVA, Tomáš HONEK, Víta ŽAMPACHOVÁ, Iva SVOBODOVÁ, Tomáš FREIBERGER and Lenka ŠPINAROVÁ. Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial. \textit{Bratislava Medical Journal - Bratislavské lekárske listy}. BRATISLAVA: Univerzita Komenského, 2022, vol.~123, No~1, p.~37-43. ISSN~0006-9248. Available from: https://dx.doi.org/10.4149/BLL\_{}2022\_{}006.

Detailed Information on Publication Record